EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Proton pump inhibitors: Understanding the associated risks and benefits of long-term use

Kristina M Thurber, Ashley O Otto, Shawna L Stricker

American Journal of Health-System Pharmacy · 08.04.2023 · 80 (8) · 487-494

DOI: 10.1093/ajhp/zxad009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 11.01.2023. Verfasst von Kristina M Thurber und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: COVID-19, Gastrointestinal Diseases, Fractures, Bone. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Proton pump inhibitors (PPIs) are widely prescribed medications. Various adverse clinical effects of PPIs have been reported in the literature, particularly over the past decade. The purpose of this article is to review published data primarily describing adverse effects associated with PPI use and to help clinicians determine which patients may still benefit from therapy despite safety concerns. Summary Associations between PPIs and the following have been described: bone fracture, acute and chronic kidney disease, gastrointestinal infections, deficiencies in vitamin B12 and magnesium, and coronavirus disease 2019 and respiratory infections. For inclusion in this review, studies must have evaluated potential adverse events associated with PPIs as a primary or secondary objective. Increased risks of bone fracture, acute and chronic kidney disease, gastrointestinal infections, and magnesium deficiency were consistently reported, albeit mostly in studies involving low-quality data (case-control and/or observational studies) and subject to bias. In the only pertinent randomized controlled trial to date, chronic pantoprazole use was associated with a greater risk of enteric infections relative to placebo use; there was no significant between-group difference in any other adverse event evaluated. PPIs continue to be recommended by the American College of Gastroenterology as a first-line treatment for management of gastroesophageal reflux disease and in the acute period following upper gastrointestinal and ulcer bleeding.

Conclusion

Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Gastrointestinal DiseasesFractures, BoneHumansProton Pump InhibitorsRisk AssessmentRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

adverse drug eventbone fractureshypomagnesemiakidney diseasesproton pump inhibitorsvitamin B12 deficiency

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
  • Department of Pharmacy, Nebraska Medicine, Omaha, NE, USA.

Zitieren

APA

Thurber, K. M., Otto, A. O., & Stricker, S. L. (2023). Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. American Journal of Health-System Pharmacy, 80(8), 487-494. https://doi.org/10.1093/ajhp/zxad009

Vancouver

Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. American Journal of Health-System Pharmacy. 2023;80(8):487-494. doi:10.1093/ajhp/zxad009

BibTeX
@article{Thurber2023,
  author = {Thurber, Kristina M and Otto, Ashley O and Stricker, Shawna L},
  title = {Proton pump inhibitors: Understanding the associated risks and benefits of long-term use},
  journal = {American Journal of Health-System Pharmacy},
  year = {2023},
  volume = {80},
  number = {8},
  pages = {487--494},
  doi = {10.1093/ajhp/zxad009}
}
Kostenlos starten →